生物技术公司Citryll筹集85万欧元,以推进新的免疫紊乱炎疗法。 Biotech firm Citryll raises €85M to advance new inflammation therapy for immune disorders.

Citryll生物技术公司已获得8 500万欧元的系列B资金,用于推进针对风湿性关节炎和隐蔽性炎等免疫性疾病中的炎症的新疗法。 Biotech firm Citryll has secured €85 million in Series B funding to advance its new therapy targeting inflammation in immune disorders like rheumatoid arthritis and hidradenitis suppurativa. 该基金由Johnson & Johnson和其他人牵头,将支持第2a阶段CIT-013研究。 CIT-013是首创型抗体,针对的是神经脊髓外细胞裂缝(NETs)。 Led by Johnson & Johnson and others, the funding will support Phase 2a studies of CIT-013, a first-of-its-kind antibody aimed at Neutrophil Extracellular Traps (NETs). 在目前药物不足的情况下,这种疗法可以提供一种新的治疗选择。 This therapy could offer a new treatment option where current drugs fall short.